Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors
February 2023
in “
Frontiers in immunology
”
immune checkpoint inhibitors cutaneous immune-related adverse events rashes pruritus vitiligo-like depigmentation bullous diseases alopecia T cell activation proinflammatory cytokines corticosteroids immunomodulators ICIs skin reactions itching skin depigmentation blistering diseases hair loss steroids
TLDR Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
Immune checkpoint inhibitors (ICIs) used in cancer therapy can cause various cutaneous immune-related adverse events (irAEs), such as rashes, pruritus, vitiligo-like depigmentation, bullous diseases, and alopecia. These skin reactions, which occur in 30-60% of patients depending on the ICI, are linked to better tumor responses and improved survival rates, particularly in metastatic melanoma. The exact mechanisms are unclear but may involve T cell activation and proinflammatory cytokines. Effective management of these dermatologic toxicities, including the use of corticosteroids and immunomodulators, is crucial for patient comfort and continued treatment efficacy.
